Uniqure NV (NASDAQ:QURE) has been given a consensus recommendation of “Buy” by the eleven analysts that are presently covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $20.29.
A number of equities research analysts have recently weighed in on QURE shares. Zacks Investment Research lowered shares of Uniqure from a “hold” rating to a “sell” rating in a research note on Wednesday, October 18th. Leerink Swann lifted their price target on shares of Uniqure from $17.00 to $19.00 and gave the company an “outperform” rating in a research report on Friday, October 20th. HC Wainwright set a $28.00 price target on shares of Uniqure and gave the company a “buy” rating in a research report on Thursday, December 7th. BidaskClub raised shares of Uniqure from a “hold” rating to a “buy” rating in a research report on Wednesday, December 27th. Finally, ValuEngine raised shares of Uniqure from a “sell” rating to a “hold” rating in a research report on Tuesday, December 26th.
Shares of Uniqure (QURE) traded down $0.23 on Friday, hitting $19.17. 624,665 shares of the stock were exchanged, compared to its average volume of 383,774. The company has a market cap of $597.52, a price-to-earnings ratio of -7.34 and a beta of 0.57. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.64 and a quick ratio of 3.64. Uniqure has a 52-week low of $4.72 and a 52-week high of $21.35.
Institutional investors have recently modified their holdings of the business. SG Americas Securities LLC purchased a new position in Uniqure in the fourth quarter worth about $119,000. JPMorgan Chase & Co. raised its holdings in Uniqure by 33.5% in the second quarter. JPMorgan Chase & Co. now owns 58,481 shares of the biotechnology company’s stock worth $362,000 after buying an additional 14,659 shares during the last quarter. Virtus Fund Advisers LLC purchased a new position in Uniqure in the fourth quarter worth about $389,000. OxFORD Asset Management LLP purchased a new position in Uniqure in the third quarter worth about $399,000. Finally, Mangrove Partners raised its holdings in Uniqure by 167.4% in the third quarter. Mangrove Partners now owns 106,634 shares of the biotechnology company’s stock worth $1,024,000 after buying an additional 66,763 shares during the last quarter. 24.97% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Uniqure NV (QURE) Given Average Recommendation of “Buy” by Analysts” was posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2018/02/10/uniqure-nv-qure-given-average-recommendation-of-buy-by-analysts.html.
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.